摘要
目的:旨在揭示C-C基序趋化因子配体14(CCL14)在肺腺癌组织中的表达,及其在肺腺癌进展和免疫浸润中的作用价值。方法:使用UALCAN、Timer、GEPIA和TISIDB数据库探究CCL14在肺腺癌进展和免疫浸润中的作用价值。结果:CCL14在肺腺癌组织中的表达水平下降,且与肺腺癌患者临床分期、性别、吸烟史、组织学亚型和肿瘤蛋白p53(TP53)突变相关。CCL14表达水平下降的肺腺癌患者预后不良。CCL14表达水平与肺腺癌纯度、免疫B细胞、CD4^(+)T细胞、CD8^(+)T细胞、巨噬细胞、树突状细胞和嗜中性粒细胞水平相关。CCL14表达水平与肺腺癌免疫浸润细胞标志物相关。CCL14可能参与嗜中性粒细胞趋化性、白细胞趋化性、淋巴细胞趋化性、调节炎症反应、细胞因子与细胞因子受体的相互作用和趋化因子信号通路参与肺腺癌进展。结论:CCL14在肺腺癌组织中的表达水平降低,升高CCL14表达的肺腺癌患者倾向于较好的预后。CCL14表达水平与肿瘤纯度和免疫浸润细胞密切相关。表明CCL14可能是肺腺癌患者预后和免疫浸润细胞标志物。
Objective:To reveal the expression of C-C motif chemokine ligand 14(CCL14)in lung adenocarcinoma and its role in the progression of lung adenocarcinoma and Immune infiltration.Methods:UALCAN,Timer,GEPIA and TISIDB databases were used to explore the role of CCL14 in lung adenocarcinoma progression and immune infiltration.Results:Expression of CCL14 in lung adenocarcinoma tissue decreased,and it was related to clinical stage,sex,smoking history,histological subtype and tumor protein p53(TP53)mutation in lung adenocarcinoma patients.Lung adenocarcinoma patients with decreased expression of CCL14 had a poor prognosis.Level of CCL14 expression was correlated with lung adenocarcinoma purity,immune B cells,CD4^(+)T cells,CD8^(+)T cells,macrophages,dendritic cells and neutrophils.Level of CCL14 expression was correlated with lung adenocarcinoma immune cell infiltration markers.CCL14 was involved in lung adenocarcinoma progression via neutrophil chemotaxis,leukocyte chemotaxis,lymphocyte chemotaxis,regulation of inflammatory response,interaction between cytokines and cytokine receptors and chemokine signaling pathway.Conclusion:Expression of CCL14 in lung adenocarcinoma tissue decreased,while the lung adenocarcinoma patients with increased expression of CCL14 tended to have a better prognosis.Expression level of CCL14 was closely related to tumor purity and immune cell infiltration.This indicates that CCL14 may be a marker of prognosis and immune infiltration in patients with lung adenocarcinoma.
作者
刘华松
贺方丽
徐兰兰(指导)
LIU Hua-Song;HE Fang-Li;XU Lan-Lan(Department of Cardiothoracic Surgery,Taihe Hospital,Hubei University of Medicine,Shiyan 442012,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2021年第24期2993-2998,3004,共7页
Chinese Journal of Immunology
基金
湖北省卫生健康委项目(WJ2019Q014)。
关键词
CCL14
肺腺癌
预后
免疫浸润
CCL14
Lung adenocarcinoma
Prognosis
Immune infiltration
作者简介
刘华松,男,博士,副主任医师,主要从事癌症基础与免疫机制研究,E-mail:Huasong819@qq.com;通信作者:徐兰兰,女,硕士,副教授,主要从事癌症基础与免疫机制研究,E-mail:215518542@qq.com。
